Exploring the mechanism of Bu Zhong Yi Qi Tang in the treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) based on network pharmacology and molecular docking

Background: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common and persistent condition affecting the male urinary system, with a global prevalence ranging from 2% to 10%. This study aims to investigate the therapeutic mechanisms of Bu Zhong Yi Qi Tang (BZYQT) in treating CP/CPPS using network pharmacology and molecular docking techniques. Methods: The active compounds and their corresponding target proteins of BZYQT were identified and screened using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). Targets associated with CP/CPPS were determined through GeneCards, the Therapeutic Target Database (TTD), Online Mendelian Inheritance in Man (OMIM), and the Pharmacogenomics Knowledgebase (PharmGKB). Overlapping targets between BZYQT and CP/CPPS were analyzed using the STRING database to construct a protein-protein interaction (PPI) network. Key targets were further subjected to Gene Ontology (GO) functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. Molecular docking studies were conducted to validate the interactions between core active compounds and key targets. In vitro experiments were performed to confirm the therapeutic efficacy of BZYQT in treating CP/CPPS. Results: The study identified 103 active compounds in BZYQT and 2064 potential target proteins. A total of 1020 CP/CPPS-related targets were retrieved from GeneCards, OMIM, TTD, and PharmGKB, leading to the identification of 73 overlapping targets and 5 core targets. GO enrichment analysis revealed that these targets are involved in inflammatory responses, apoptosis, oxidative stress, and cell proliferation. KEGG pathway analysis highlighted associations with pathways such as the ErbB signaling pathway. Molecular docking results suggested that kaempferol, an active compound in BZYQT, exhibited the highest binding affinity with the target proteins. Experimental validation demonstrated that kaempferol effectively inhibited the expression of EGFR, MMP9, TNF-α, and IL-6. Conclusions: BZYQT exhibits significant therapeutic potential in the treatment of CP/CPPS through its multi-target and multi-pathway mechanisms. The active compound kaempferol plays a crucial role in alleviating pathological changes in CP/CPPS by downregulating the expression of MMP9, EGFR, IL-6, and TNF-α. These findings provide a molecular basis for the application of traditional Chinese medicine in the management of CP/CPPS.

BZYQT; Chronic prostatitis; Chronic pelvic pain syndrome; Network pharmacology

[1] Krieger JN, Lee SW, Jeon J, Cheah PY, Liong ML, Riley DE. Epidemiology of prostatitis. International Journal of Antimicrobial Agents. 2008; 31: S85–S90.

[2] Krieger JN, Ross SO, Riley DE. Chronic prostatitis: epidemiology and role of infection. Urology. 2002; 60: 8–12; discussion 13.

[3] Lam JC, Stokes W. Acute and chronic prostatitis. American Family Physician. 2024; 110: 45–51.

[4] Healy R, Thorne C, Manjunath A. Chronic prostatitis (chronic pelvic pain syndrome). The BMJ. 2023; 383: e073908.

[5] Oseni SO, Naar C, Pavlović M, Asghar W, Hartmann JX, Fields GB, et al. The molecular basis and clinical consequences of chronic inflammation in prostatic diseases: prostatitis, benign prostatic hyperplasia, and prostate cancer. Cancers. 2023; 15: 3110.

[6] Šutulović N, Vesković M, Puškaš N, Zubelić A, Jerotić D, Šuvakov S, et al. Chronic prostatitis/chronic pelvic pain syndrome induces depression-like behavior and learning-memory impairment: a possible link with decreased hippocampal neurogenesis and astrocyte activation. Oxidative Medicine and Cellular Longevity. 2023; 2023: 3199988.

[7] Lihua J, Haodan K, Yuan XU. Efficacy of Buzhong Yiqi decoction on benign prostatic hyperplasia and its possible mechanism. Journal of Traditional Chinese Medicine. 2023; 43: 533–541.

[8] Peng YP, Huang W, Huang HH, Xing YT. Effect of Suoquan Wan combined with Buzhong Yiqi Tang on urodynamics in patients with urinary incontinence after surgery for benign prostatic hyperplasia. Traditional Chinese Medicine and Clinical Pharmacology. 2021; 32: 428–434. (In Chinese)

[9] Cheng YY, Hsieh CH, Tsai TH. Concurrent administration of anticancer chemotherapy drug and herbal medicine on the perspective of pharmacokinetics. Journal of Food and Drug Analysis. 2018; 26: S88–S95.

[10] Hu L, Yamamoto M, Chen J, Duan H, Du J, He L, et al. Integrating network pharmacology and experimental verification to decipher the immunomodulatory effect of Bu-Zhong-Yi-Qi-Tang against poly (I:C)-induced pulmonary inflammation. Frontiers in Pharmacology. 2022; 13: 1015486.

[11] Sekiya M, Kiyohara H, Maruyama H, Yabe T, Yamada H. Modulation of chemokine expression on intestinal epithelial cells by Kampo (traditional Japanese herbal) medicine, Hochuekkito, and its active ingredients. Journal of Natural Medicines. 2013; 67: 626–635.

[12] Hu L, Chen G, Chen J, Zou Z, Qiu Y, Du J, et al. Quantitative ternary network-oriented discovery of Q-markers from traditional Chinese medicine prescriptions: Bu-Zhong-Yi-Qi-Tang as a case study. Phytomedicine. 2024; 133: 155918.

[13] Chen S, Deng B, Zhao F, You H, Liu Y, Xie L, et al. Silencing SPP1 in M2 macrophages inhibits the progression of castration-resistant prostate cancer via the MMP9/TGFβ1 axis. Translational Andrology and Urology. 2024; 13: 1239–1255.

[14] Gui J, Zhou H, Li S, Chen A, Liu Q, Zhu L, et al. Current evidence on the relationships among five polymorphisms in the matrix metalloproteinases genes and prostate cancer risk. Scientific Reports. 2024; 14: 11355.

[15] Lange S, Inal JM, Kraev I, Dart DA, Uysal-Onganer P. Low magnetic field exposure alters prostate cancer cell properties. Biology. 2024; 13: 734.

[16] Girard N. EGFR-mutated NSCLC: a roadmap to treatment sequences. Med. 2024; 5: 1044–1047.

[17] Rao C, Hu R, Hu Y, Jiang Y, Zou X, Tang H, et al. Theoretical exploring of potential mechanisms of antithrombotic ingredients in danshen-chishao herb-pair by network pharmacological study, molecular docking and zebrafish models. Chinese Medicine. 2024; 19: 100.

[18] Hua X, Zhang J, Chen J, Feng R, Zhang L, Chen X, et al. Sodium butyrate alleviates experimental autoimmune prostatitis by inhibiting oxidative stress and NLRP3 inflammasome activation via the Nrf2/HO-1 pathway. Prostate. 2024; 84: 666–681.

[19] Libero ML, Montero-Hidalgo AJ, Recinella L, Luque RM, Generali D, Acquaviva A, et al. The protective effects of an aged black garlic water extract on the prostate. Nutrients. 2024; 16: 3025.

[20] Villar A, Silva-Fuentes F, Mulà A, Zangara A. Anti-inflammatory potential of Pygeum africanum bark extract: an in vitro study of cytokine release by lipopolysaccharide-stimulated human peripheral blood mononuclear cells. International Journal of Molecular Sciences. 2024; 25: 8298.

[21] Liu Y, Jia Z, Wang Y, Song Y, Yan L, Zhang C. Exploring the mechanisms of Huangqin Qingfei Decoction on acute lung injury by LC-MS combined network pharmacology analysis. Phytomedicine. 2024; 134: 155979.

[22] Al-Roub A, Akhter N, Al-Rashed F, Wilson A, Alzaid F, Al-Mulla F, et al. TNFα induces matrix metalloproteinase-9 expression in monocytic cells through ACSL1/JNK/ERK/NF-kB signaling pathways. Scientific Reports. 2023; 13: 14351.

[23] Mohammad SI, Aldosari BN, Mehanni MM, El-Gendy AO, Hozayen WG, Afzal O, et al. Fabrication and application of targeted ciprofloxacin nanocarriers for the treatment of chronic bacterial prostatitis. International Journal of Pharmaceutics: X. 2024; 7: 100247.